Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

337 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Transcription regulators and ultra-rare and other rare translocation-related sarcomas treated with trabectedin: A proof of principle from a post-hoc analysis.
Palmerini E, Sanfilippo R, Grignani G, Buonadonna A, Romanini A, Badalamenti G, Ferraresi V, Vincenzi B, Comandone A, Pizzolorusso A, Brunello A, Gelsomino F, De Pas T, Ibrahim T, Gurrieri L, Grosso F, Zanelli F, Pantaleo MA, Milesi L, Ciuffreda L, Ferrari V, Marchesi E, Quattrini I, Righi A, Setola E, Carretta E, Casali PG, Picci P, Ferrari S. Palmerini E, et al. Among authors: casali pg. Front Oncol. 2022 Dec 8;12:1042479. doi: 10.3389/fonc.2022.1042479. eCollection 2022. Front Oncol. 2022. PMID: 36568164 Free PMC article.
Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors.
Forni C, Minuzzo M, Virdis E, Tamborini E, Simone M, Tavecchio M, Erba E, Grosso F, Gronchi A, Aman P, Casali P, D'Incalci M, Pilotti S, Mantovani R. Forni C, et al. Mol Cancer Ther. 2009 Feb;8(2):449-57. doi: 10.1158/1535-7163.MCT-08-0848. Epub 2009 Feb 3. Mol Cancer Ther. 2009. PMID: 19190116
PML down-regulation in soft tissue sarcomas.
Vincenzi B, Perrone G, Santini D, Grosso F, Silletta M, Frezza A, Rossi S, Russo A, Rabitti C, Gebbia N, Badalamenti G, Casali P, Muda AO, Dei Tos AP, Tonini G. Vincenzi B, et al. J Cell Physiol. 2010 Sep;224(3):644-8. doi: 10.1002/jcp.22161. J Cell Physiol. 2010. PMID: 20578240
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study.
Grignani G, Palmerini E, Dileo P, Asaftei SD, D'Ambrosio L, Pignochino Y, Mercuri M, Picci P, Fagioli F, Casali PG, Ferrari S, Aglietta M. Grignani G, et al. Among authors: casali pg. Ann Oncol. 2012 Feb;23(2):508-16. doi: 10.1093/annonc/mdr151. Epub 2011 Apr 28. Ann Oncol. 2012. PMID: 21527590 Free article. Clinical Trial.
337 results